ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

Tafasitamab/Lenalidomide for DLBCL: Which Patients and What to Expect

Amit Mehta

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Bispecifics for LBCL: Guidance for Management of Toxicities in the C…

UChicago Medicine

J. Crombie

Updates in CAR-T Therapy for Aggressive Lymphomas

Vanderbilt University Medical Center (VUMC)

B. Dholaria

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

Hematopathology Tumor Board: Case Studies and Diagnostic Challenges …

UChicago Medicine

G. Venkataraman, A. Perry, K. Cahill, A. Akmatbekov, L. Wu